$ANIX

KUMAR AMIT purchased $15K of ANIX

KUMAR AMIT (Chief Executive Officer) purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $3.04 on 2026-07-10.

Original reporting
SEC EDGAR · KUMAR AMIT
Published Jul 13, 2026, 12:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 1:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The newest fact is the CEO’s disclosed open-market purchase (5,000 shares at $3.0400) and the post-transaction share count (635,812).

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the filing does not provide intent, timing constraints, or whether the purchase was part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-07-13, covering a purchase dated 2026-07-10.

Background

This is an SEC Form 4 insider transaction disclosure for Anixa Biosciences, Inc.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

CEO Kumar Amit filed a Form 4 open-market purchase of 5,000 shares at $3.0400 on 2026-07-10, totaling $15,200.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The article is a primary-source Form 4 showing a direct open-market purchase by the CEO, but the transaction value ($15.2k) is relatively small versus typical market-moving thresholds.

Market effects

No clear sector read-through from a single small insider purchase.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine and may reflect diversification or planned liquidity needs rather than a strong forward-looking signal.

Key entities

  • Anixa Biosciences Inc

    Subject of the Form 4 insider transaction disclosure.

  • Kumar Amit

    CEO and director who purchased 5,000 shares open-market.

Related articles